Across TCGA pan-cancer cohorts, PRRG3 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRRG3 data layer compared with 20 for mass-spec protein and 10 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher PRRG3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PRRG3 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
GBM and LSCC are the cancer types where PRRG3 mass-spec protein most reproducibly stratifies survival.